KR101363875B1 - Ｈｉｖ 통합효소 억제 활성을 가지는 다환식카르바모일피리돈 유도체 - Google Patents

Ｈｉｖ 통합효소 억제 활성을 가지는 다환식카르바모일피리돈 유도체 Download PDF

Info

Publication number
KR101363875B1
KR101363875B1 KR1020077027734A KR20077027734A KR101363875B1 KR 101363875 B1 KR101363875 B1 KR 101363875B1 KR 1020077027734 A KR1020077027734 A KR 1020077027734A KR 20077027734 A KR20077027734 A KR 20077027734A KR 101363875 B1 KR101363875 B1 KR 101363875B1
Authority
KR
South Korea
Prior art keywords
methyl
hydroxy
dioxo
substituted
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020077027734A
Other languages
English (en)
Korean (ko)
Other versions
KR20080009733A (ko
Inventor
브라이언 알빈 존스
타카시 카와스지
테루히코 타이시
요시유키 타오다
Original Assignee
시오노기세야쿠 가부시키가이샤
비이브 헬쓰케어 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37215098&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101363875(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 시오노기세야쿠 가부시키가이샤, 비이브 헬쓰케어 컴퍼니 filed Critical 시오노기세야쿠 가부시키가이샤
Publication of KR20080009733A publication Critical patent/KR20080009733A/ko
Application granted granted Critical
Publication of KR101363875B1 publication Critical patent/KR101363875B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020077027734A 2005-04-28 2006-04-28 Ｈｉｖ 통합효소 억제 활성을 가지는 다환식카르바모일피리돈 유도체 Active KR101363875B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2005131161 2005-04-28
JPJP-P-2005-00131161 2005-04-28
JPJP-P-2005-00312076 2005-10-27
JP2005312076 2005-10-27
PCT/US2006/016604 WO2006116764A1 (en) 2005-04-28 2006-04-28 Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020137028203A Division KR101504998B1 (ko) 2005-04-28 2006-04-28 Ｈｉｖ 통합효소 억제 활성을 가지는 다환식 카르바모일피리돈 유도체

Publications (2)

Publication Number Publication Date
KR20080009733A KR20080009733A (ko) 2008-01-29
KR101363875B1 true KR101363875B1 (ko) 2014-02-21

Family

ID=37215098

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020157036007A Active KR101848819B1 (ko) 2005-04-28 2006-04-28 Ｈｉｖ 통합효소 억제 활성을 가지는 다환식 카르바모일피리돈 유도체
KR1020137028203A Active KR101504998B1 (ko) 2005-04-28 2006-04-28 Ｈｉｖ 통합효소 억제 활성을 가지는 다환식 카르바모일피리돈 유도체
KR1020077027734A Active KR101363875B1 (ko) 2005-04-28 2006-04-28 Ｈｉｖ 통합효소 억제 활성을 가지는 다환식카르바모일피리돈 유도체
KR1020147017235A Active KR101580310B1 (ko) 2005-04-28 2006-04-28 Ｈｉｖ 통합효소 억제 활성을 가지는 다환식 카르바모일피리돈 유도체

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020157036007A Active KR101848819B1 (ko) 2005-04-28 2006-04-28 Ｈｉｖ 통합효소 억제 활성을 가지는 다환식 카르바모일피리돈 유도체
KR1020137028203A Active KR101504998B1 (ko) 2005-04-28 2006-04-28 Ｈｉｖ 통합효소 억제 활성을 가지는 다환식 카르바모일피리돈 유도체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020147017235A Active KR101580310B1 (ko) 2005-04-28 2006-04-28 Ｈｉｖ 통합효소 억제 활성을 가지는 다환식 카르바모일피리돈 유도체

Country Status (30)

Country Link
US (22) US8129385B2 (enExample)
EP (9) EP1874117B8 (enExample)
JP (2) JP4295353B2 (enExample)
KR (4) KR101848819B1 (enExample)
AU (1) AU2006239177B8 (enExample)
BE (1) BE2021C519I2 (enExample)
BR (1) BRPI0610030B8 (enExample)
CA (1) CA2606282C (enExample)
CY (7) CY1115151T1 (enExample)
DK (6) DK3372281T3 (enExample)
EA (1) EA014162B1 (enExample)
ES (7) ES2437268T3 (enExample)
FI (1) FIC20210017I1 (enExample)
FR (1) FR14C0041I2 (enExample)
HK (2) HK1249742A1 (enExample)
HU (6) HUE037795T2 (enExample)
IL (4) IL186555A (enExample)
LT (5) LT3045206T (enExample)
LU (2) LU92446I2 (enExample)
MA (1) MA29460B1 (enExample)
MX (2) MX302718B (enExample)
NL (2) NL300676I2 (enExample)
NO (5) NO339525B1 (enExample)
NZ (1) NZ562339A (enExample)
PL (5) PL3372281T3 (enExample)
PT (5) PT3284520T (enExample)
SI (6) SI3187225T1 (enExample)
TW (1) TWI378931B (enExample)
VN (1) VN34404A1 (enExample)
WO (1) WO2006116764A1 (enExample)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8598193B2 (en) 2003-12-24 2013-12-03 Biota Scientific Management Pty Ltd. Polycyclic agents for the treatment of respiratory syncytial virus infections
US7273859B2 (en) * 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
PL3372281T3 (pl) * 2005-04-28 2021-12-27 Viiv Healthcare Company Policykliczne pochodne karbamoilopirydonu o aktywności inhibitorowej wobec integrazy HIV
EP1881825B1 (en) 2005-05-10 2013-07-24 Merck Sharp & Dohme Corp. Hiv integrase inhibitors
US7939537B2 (en) 2005-10-04 2011-05-10 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. HIV integrase inhibitors
BRPI0617842A2 (pt) 2005-10-27 2011-08-09 Shionogi & Co composto ou um sal farmaceuticamente aceitável ou um solvato do mesmo, e, composição farmacêutica
TWI423972B (zh) 2006-09-28 2014-01-21 Biota Scient Management 治療呼吸系融合細胞病毒感染之多環劑
NZ585297A (en) * 2007-11-15 2012-06-29 Gilead Sciences Inc Inhibitors of human immunodeficiency virus replication
ATE541841T1 (de) 2007-11-15 2012-02-15 Boehringer Ingelheim Int Inhibitoren der replikation des human immunodeficiency virus
WO2009062285A1 (en) 2007-11-16 2009-05-22 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
PL2320908T3 (pl) 2008-07-25 2014-06-30 Viiv Healthcare Co Proleki dolutegrawiru
KR101772610B1 (ko) * 2008-07-25 2017-09-12 비이브 헬쓰케어 컴퍼니 화합물
WO2010011818A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010011815A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010011816A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
AU2014277831C1 (en) * 2008-12-11 2022-10-06 Shionogi & Co. Ltd. Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
JP5629268B2 (ja) * 2008-12-11 2014-11-19 塩野義製薬株式会社 マルトールエーテルの製造方法および中間体
JP5572168B2 (ja) 2008-12-11 2014-08-13 ビーブ・ヘルスケア・カンパニー カルバモイルピリドンｈｉｖインテグラーゼ阻害剤の製造方法および中間体
US8624023B2 (en) * 2008-12-11 2014-01-07 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
PL2444400T3 (pl) 2009-06-15 2018-08-31 Shionogi & Co., Ltd. Podstawiona policykliczna pochodna karbamoilopirydonowa
WO2011011483A1 (en) * 2009-07-22 2011-01-27 Glaxosmithkline Llc Chemical compounds
AU2010305805B2 (en) 2009-10-13 2014-04-03 Elanco Animal Health Ireland Limited Macrocyclic integrase inhibitors
AU2014202405B2 (en) * 2010-01-27 2016-02-25 Viiv Healthcare Company Antiviral therapy
AU2014202404C1 (en) * 2010-01-27 2022-06-23 Viiv Healthcare Company Antiviral therapy
EA032868B1 (ru) * 2010-01-27 2019-07-31 Вайв Хелткер Компани Комбинация для лечения вич-инфекции
TWI508968B (zh) * 2010-02-08 2015-11-21 Biota Scient Management 用於治療呼吸道融合性病毒感染的化合物
NZ601847A (en) * 2010-02-26 2014-03-28 Japan Tobacco Inc 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor
TWI582097B (zh) 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
WO2011121105A1 (en) 2010-04-02 2011-10-06 Tibotec Pharmaceuticals Macrocyclic integrase inhibitors
JP5766690B2 (ja) * 2010-04-12 2015-08-19 塩野義製薬株式会社 インテグラーゼ阻害活性を有するピリドン誘導体
WO2012006104A2 (en) 2010-06-28 2012-01-12 Academia Sinica, Taiwan Compounds and methods for treating tuberculosis infection
DK3456721T3 (da) 2010-08-05 2021-04-26 Shionogi & Co Fremgangsmåde til at fremstille forbindelser som har hiv-integrase-inhiberende aktivitet.
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
US8987441B2 (en) 2010-09-24 2015-03-24 Shionogi & Co., Ltd. Substituted polycyclic carbamoyl pyridone derivative prodrug
US8796303B2 (en) 2010-11-26 2014-08-05 Biota Scientific Management Pty Ltd. Imidazo[2,1-G][1,7]naphthyridines for treating respiratory syncytial virus infections
US20140213553A1 (en) * 2011-05-03 2014-07-31 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
ES2613180T3 (es) * 2011-09-14 2017-05-23 Mapi Pharma Limited Forma amorfa de la sal sódica dolutegravir
RU2014113230A (ru) * 2011-10-12 2015-11-20 Шионоги Энд Ко., Лтд. Полициклическое производное пиридона, обладающее ингибирующей активностью в отношении интегразы
JP6242810B2 (ja) 2011-12-28 2017-12-06 グローバル・ブラッド・セラピューティクス・インコーポレイテッドＧｌｏｂａｌ Ｂｌｏｏｄ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 置換ベンズアルデヒド化合物および組織酸素化の増加におけるそれらの使用方法
WO2013102145A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
EP2931730B1 (en) * 2012-12-17 2019-08-07 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as hiv integrase inhibitors
SI3067358T1 (sl) * 2012-12-21 2019-12-31 Gilead Sciences, Inc. Policiklične spojine karbamoilpiridona in njihova farmacevtska uporaba
AR094311A1 (es) 2012-12-27 2015-07-22 Japan Tobacco Inc Derivados de tetrahidroespiro-ciclopropil-pirido[1,2-a]pirazina inhibidores de la integrasa del hiv
CA2897137A1 (en) 2013-02-18 2014-08-21 Ratiopharm Gmbh Solid pharmaceutical dosage form of dolutegravir
EP2767272A1 (en) 2013-02-18 2014-08-20 Ratiopharm GmbH Solid pharmaceutical dosage form of dolutegravir
US9573965B2 (en) 2013-02-19 2017-02-21 Aurobindo Pharma Ltd Process for the preparation of Dolutegravir
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CN105246477A (zh) 2013-03-15 2016-01-13 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EA037091B1 (ru) 2013-03-15 2021-02-04 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
MX379228B (es) 2013-03-15 2025-03-10 Global Blood Therapeutics Inc Compuestos y usos de estos para la modulación de la hemoglobina.
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9493479B2 (en) 2013-04-16 2016-11-15 Merck Sharp & Dohme Corp. Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors
EP3008044B1 (en) * 2013-06-13 2018-11-21 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
WO2015001572A2 (en) 2013-07-04 2015-01-08 Hetero Research Foundation Process for the preparation of intermediate of dolutegravir
AU2014286993B2 (en) 2013-07-12 2018-10-25 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their use for the treatment of HIV infections
NO2865735T3 (enExample) 2013-07-12 2018-07-21
EP3022209B1 (en) 2013-07-17 2018-03-07 ratiopharm GmbH Dolutegravir potassium salt
WO2015019310A1 (en) 2013-08-07 2015-02-12 Mylan Laboratories Ltd Process for the preparation of dolute-gravir and intermediates thereof
WO2015039348A1 (en) * 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
HK1221648A1 (zh) 2013-09-27 2017-06-09 Merck Sharp & Dohme Corp. 用作hiv整合酶抑制劑的取代喹嗪衍生物
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
WO2015092752A1 (en) 2013-12-20 2015-06-25 Mylan Laboratories Ltd. Novel crystalline form of dolutegravir sodium
WO2015089847A1 (en) * 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
US9808428B2 (en) 2014-01-14 2017-11-07 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
IN2014CH00247A (enExample) * 2014-01-21 2015-08-14 Laurus Labs Private Ltd
CN114213390A (zh) 2014-02-07 2022-03-22 全球血液疗法股份有限公司 一种化合物的结晶多晶型物
WO2015138933A1 (en) 2014-03-13 2015-09-17 Assia Chemical Industries Ltd. Solid state forms of dolutegravir sodium
CN106866702B (zh) * 2014-03-19 2019-03-19 杭州普晒医药科技有限公司 德罗格韦钠盐的晶型及其制备方法
IN2014MU00916A (enExample) 2014-03-20 2015-09-25 Cipla Ltd
WO2015177537A1 (en) * 2014-05-20 2015-11-26 Cipla Limited Process for preparing polycyclic carbamoyl pyridone derivatives and intermediates thereof
NO2717902T3 (enExample) * 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI744723B (zh) * 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
WO2016027879A1 (ja) * 2014-08-22 2016-02-25 塩野義製薬株式会社 インテグラーゼ阻害活性を有する多環性ピリドン誘導体
WO2016057866A1 (en) 2014-10-09 2016-04-14 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
WO2016092527A1 (en) * 2014-12-12 2016-06-16 Sun Pharmaceutical Industries Limited A process for the preparation of dolutegravir
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
EP3045461A1 (en) 2015-01-16 2016-07-20 LEK Pharmaceuticals d.d. Processes for preparing dolutegravir and analogues thereof
KR20170113650A (ko) 2015-02-06 2017-10-12 밀란 래버러토리스 리미티드 돌루테그라비어의 제조 방법
CZ201599A3 (cs) 2015-02-13 2016-08-24 Zentiva, K.S. Pevné formy solí dolutegraviru a způsob jejich přípravy
WO2016154527A1 (en) * 2015-03-26 2016-09-29 Merck Sharp & Dohme Corp. Phosphate-substituted quinolizine derivatives useful as hiv integrase inhibitors
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
CA2980362C (en) 2015-04-02 2020-02-25 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
WO2016175224A1 (ja) * 2015-04-28 2016-11-03 塩野義製薬株式会社 置換された多環性ピリドン誘導体およびそのプロドラッグ
WO2016187788A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
CZ2015537A3 (cs) 2015-08-04 2017-02-15 Zentiva, K.S. Pevné formy amorfního dolutegraviru
EP3337479B1 (en) 2015-08-19 2023-12-13 Laurus Labs Limited Novel polymorphs of dolutegravir and salts thereof
CN108348473B (zh) 2015-11-09 2021-06-18 吉利德科学公司 治疗人免疫缺陷病毒的治疗组合物
WO2017087257A1 (en) 2015-11-17 2017-05-26 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as hiv integrase inhibitors
FI3383392T3 (fi) 2015-12-04 2025-09-11 Global Blood Therapeutics Inc Annosteluohjelmat 2-hydroksi-6-((2-(1-isopropyyli-1h-pyratsol-5-yyli)pyridin-3-yyli)metoksi)bentsaldehydille
US10544155B2 (en) 2015-12-15 2020-01-28 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors
ES2742249T3 (es) 2015-12-21 2020-02-13 Lupin Ltd Proceso para la preparación de inhibidores de la integrasa de VIH
TWI752307B (zh) 2016-05-12 2022-01-11 美商全球血液治療公司 新穎化合物及製造化合物之方法
WO2017208105A1 (en) 2016-05-30 2017-12-07 Lupin Limited Novel crystalline form of dolutegravir sodium
WO2017223280A2 (en) * 2016-06-23 2017-12-28 Viiv Healthcare Company Compositions and methods for the delivery of therapeutics
WO2018029565A1 (en) 2016-08-08 2018-02-15 Hetero Labs Limited A multi-class anti-retroviral composition
WO2018029561A1 (en) 2016-08-08 2018-02-15 Hetero Labs Limited Anti-retroviral compositions
WO2018031987A1 (en) * 2016-08-12 2018-02-15 Nanjing Gator Meditech Company, Ltd. Protein kinase regulators
WO2018042332A1 (en) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
US20190216725A1 (en) * 2016-09-21 2019-07-18 Merck Shapr & Dohme Corp. Drug delivery system for the delivery of integrase inhibitors
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
JOP20190130A1 (ar) * 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
KR20190086017A (ko) 2016-12-02 2019-07-19 머크 샤프 앤드 돔 코포레이션 Hiv 인테그라제 억제제로서 유용한 트리시클릭 헤테로사이클 화합물
WO2018109786A1 (en) 2016-12-16 2018-06-21 Cipla Limited Novel polymoprphs and salts of polycyclic carbamoyl pyridone derivatives
US10786488B2 (en) 2017-01-26 2020-09-29 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as HIV integrase inhibitors
EP3363802B1 (en) 2017-02-16 2019-11-20 Sandoz AG Crystalline form of cabotegravir sodium
CN110582504A (zh) 2017-02-16 2019-12-17 桑多斯股份公司 卡博特韦钠的晶形
US20200138845A1 (en) * 2017-07-18 2020-05-07 Viiv Healthcare Company Combination Drug Therapy
KR20200031658A (ko) 2017-07-21 2020-03-24 비이브 헬쓰케어 컴퍼니 Hib 감염 및 aids를 치료하기 위한 요법
EP3661940A1 (en) 2017-09-07 2020-06-10 Cipla Limited New polymorphs of dolutegravir sodium
WO2019070059A1 (ja) 2017-10-06 2019-04-11 塩野義製薬株式会社 置換された多環性ピリドン誘導体の立体選択的な製造方法
US11839623B2 (en) 2018-01-12 2023-12-12 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
WO2019159199A1 (en) 2018-02-16 2019-08-22 Cipla Limited Continues flow process for the preparation of active pharmaceutical ingredients - polycyclic carbamoyl pyridone derivatives and intermediates thereof
US11458136B2 (en) 2018-04-09 2022-10-04 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
CN110526930B (zh) 2018-05-23 2022-06-03 莫云芬 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用
SG11202011386QA (en) * 2018-05-31 2020-12-30 Shionogi & Co Polycyclic pyridone derivative
LT3805220T (lt) 2018-05-31 2024-08-26 Shionogi & Co., Ltd Policikliniai karbamoilpiridono dariniai, skirti živ gydymui
TWI820141B (zh) * 2018-05-31 2023-11-01 日商鹽野義製藥股份有限公司 衍生物
US11634431B2 (en) 2018-07-12 2023-04-25 Laurus Labs Limited Process for purification of protected polycyclic carbamoylpyridone derivatives
WO2020072377A1 (en) 2018-10-01 2020-04-09 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease
CA3117453A1 (en) 2018-10-22 2020-04-30 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and nanoformulations thereof
CN113382737B (zh) 2018-11-29 2025-06-03 内布拉斯加大学董事会 抗病毒前药及其纳米制剂
WO2020197991A1 (en) 2019-03-22 2020-10-01 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
RU2717101C1 (ru) 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
US20200398978A1 (en) 2019-06-20 2020-12-24 Bell Helicopter Textron Inc. Low-drag rotor blade extension
US11248005B2 (en) 2019-07-08 2022-02-15 Lupin Limited Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor
JPWO2021107066A1 (enExample) 2019-11-28 2021-06-03
AU2020402659A1 (en) 2019-12-09 2022-06-02 Viiv Healthcare Company Pharmaceutical compositions comprising cabotegravir
BR112022015771A2 (pt) 2020-02-24 2022-10-11 Gilead Sciences Inc Compostos tetracíclicos para tratar a infecção por hiv
WO2025068743A1 (en) 2023-09-27 2025-04-03 ViiV Healthcare UK (No.3) Limited Pharmaceutical composition of cabotegravir
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
JP2023539344A (ja) 2020-09-01 2023-09-13 ヴィーブ、ヘルスケア、カンパニー カボテグラビルおよびレボノルゲストレルの組合せ
TW202222798A (zh) 2020-09-30 2022-06-16 美商基利科學股份有限公司 橋接三環胺甲醯基吡啶酮化合物及其用途
WO2022079739A1 (en) 2020-10-14 2022-04-21 Cipla Limited Fixed dose compositions of cabotegravir and rilpivirine
US20250296988A1 (en) 2020-12-07 2025-09-25 Viiv Healthcare Company Combination therapy
CA3202957A1 (en) 2021-01-19 2022-07-28 Hang CHU Substituted pyridotriazine compounds and uses thereof
US20250188091A1 (en) 2021-06-03 2025-06-12 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pyridone compound having integrase inhibitory activity and pharmaceutical use thereof
CN114230579A (zh) * 2021-11-12 2022-03-25 南京艾迪医药科技有限公司 多环氨基甲酰基吡啶酮衍生物及其制备方法和药物组合物
WO2023102374A1 (en) 2021-12-03 2023-06-08 Viiv Healthcase Company Process of synthesizing (r)-3-aminobutan-1-ol
TWI843506B (zh) 2022-04-06 2024-05-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
CN120936599A (zh) * 2023-01-18 2025-11-11 歌礼生物科技（杭州）有限公司 整合酶抑制剂及其应用
WO2025068912A1 (en) 2023-09-27 2025-04-03 ViiV Healthcare UK (No.3) Limited Pharmaceutical compositions
WO2025128496A1 (en) 2023-12-12 2025-06-19 Viiv Healthcare Company Crystalline form
WO2025128498A1 (en) 2023-12-12 2025-06-19 Viiv Healthcare Company Pharmaceutical compositions
WO2025181723A1 (en) 2024-03-01 2025-09-04 ViiV Healthcare UK (No.3) Limited Dosing regimen

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016927A1 (ja) 2003-08-13 2005-02-24 Japan Tobacco Inc. 含窒素縮合環化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959316A (en) * 1972-03-13 1976-05-25 Snam Progetti S.P.A. Procedure for propylene oxide synthesis
JPH0296506A (ja) * 1988-09-30 1990-04-09 Daicel Chem Ind Ltd 除草剤組成物
JP2533796B2 (ja) 1988-10-18 1996-09-11 ダイセル化学工業株式会社 ５−アルコキシピリジン−３−カルボキサミド誘導体とその製造方法及び植物成長抑制剤
JP2551472B2 (ja) 1988-10-18 1996-11-06 ダイセル化学工業株式会社 ５−アルコキシ−γ−ピロン−３−カルボキサミド誘導体とその製造方法及び植物成長抑制剤
NZ505362A (en) 1997-12-22 2004-12-24 Upjohn Co 4-hydroxyquinoline-3-carboxamides and -hydrazides useful as antiviral agents
US20040039060A1 (en) † 2000-06-14 2004-02-26 Ryuichi Kiyama Inhibitor for enzyme having two divalent metal ions as active centers
US6580562B2 (en) 2000-07-24 2003-06-17 Yazaki Corporation On-vehicle display unit
US6384263B1 (en) 2000-08-04 2002-05-07 E. I. Du Pont De Nemours And Company Process for making 3-hydroxyalkanelnitriles and conversion of the 3-hydroxyalkanelnitrile to an hydroxyaminoalkane
WO2002030426A1 (en) 2000-10-12 2002-04-18 Merck & Co., Inc. Aza- and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors
JP2003032772A (ja) 2001-07-12 2003-01-31 Foster Electric Co Ltd 耳掛け式イヤホン
DK2266958T1 (da) 2001-08-10 2016-04-04 Shionogi & Co Antiviralt middel
SI1441735T1 (sl) 2001-10-26 2006-06-30 Angeletti P Ist Richerche Bio N-substituirani hidroksipirimidinon-karboksamidniinhibitorji HIV-integraze
AU2002334205B2 (en) 2001-10-26 2007-07-05 Istituto Di Ricerche Di Biologia Molecolara P. Angeletti Spa Dihydroxypyrimidine carboxamide inhibitors of HIV integrase
EP1467970B1 (en) 2002-01-17 2007-08-22 Merck & Co., Inc. Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors
WO2004004657A2 (en) 2002-07-09 2004-01-15 Bristol-Myers Squibb Company Hiv integrase inhibitors
DE60322920D1 (de) 2002-08-13 2008-09-25 Shionogi & Co Heterocyclische verbindungen mit hiv-integrase-hemmender wirkung
EP1549315A4 (en) 2002-09-11 2007-05-23 Merck & Co Inc DIHYDROXYPYRIDOPYRAZINE-1,6-DION COMPOUNDS AS HIV INTEGRASE INHIBITORS
AU2003292437A1 (en) 2002-12-27 2004-07-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Tetrahydro-4h-pyrido(1,2-a)pyrimidines and related compounds useful as hiv integrase inhibitors
US6960680B2 (en) 2003-01-08 2005-11-01 Rhodia Chirex, Inc. Manufacture of water-soluble β-hydroxynitriles
JP2004244320A (ja) 2003-02-10 2004-09-02 Shionogi & Co Ltd 含窒素複素環抗ウイルス剤
WO2004101512A2 (en) 2003-05-13 2004-11-25 Smithkline Beecham Corporation Naphthyridine integrase inhibitors
AU2003273190A1 (en) * 2003-08-12 2005-02-25 Rachel Beijer Scheduled message service
JP4530642B2 (ja) 2003-10-31 2010-08-25 オリンパス株式会社 内視鏡装置
EP1720856B1 (en) 2004-02-11 2013-08-14 GlaxoSmithKline LLC Hiv integrase inhibitors
CN1930161A (zh) 2004-03-09 2007-03-14 P·安杰莱蒂分子生物学研究所 Hiv整合酶抑制剂
AU2005227258A1 (en) 2004-03-09 2005-10-06 Merck & Co., Inc. HIV integrase inhibitors
CN1964975B (zh) 2004-05-07 2011-11-30 默沙东公司 Hiv整合酶抑制剂
WO2006066414A1 (en) 2004-12-23 2006-06-29 Virochem Pharma Inc. Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase
US7858788B2 (en) * 2005-02-21 2010-12-28 Shionogi & Co., Ltd. Bicyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
JP5116660B2 (ja) 2005-03-31 2013-01-09 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ Ｈｉｖインテグラーゼ阻害剤
PL3372281T3 (pl) * 2005-04-28 2021-12-27 Viiv Healthcare Company Policykliczne pochodne karbamoilopirydonu o aktywności inhibitorowej wobec integrazy HIV
JP2005312076A (ja) 2005-05-26 2005-11-04 Olympus Corp 電子撮像装置
JP2009503081A (ja) 2005-08-04 2009-01-29 スミスクライン ビーチャム コーポレーション Ｈｉｖインテグラーゼ阻害薬
BRPI0617842A2 (pt) * 2005-10-27 2011-08-09 Shionogi & Co composto ou um sal farmaceuticamente aceitável ou um solvato do mesmo, e, composição farmacêutica

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016927A1 (ja) 2003-08-13 2005-02-24 Japan Tobacco Inc. 含窒素縮合環化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用

Also Published As

Publication number Publication date
DK3045206T3 (en) 2018-05-22
HK1107227A1 (en) 2008-04-03
LTC2465580I2 (enExample) 2022-10-10
FR14C0041I1 (enExample) 2014-06-27
NL300676I2 (enExample) 2016-10-11
ES2667868T3 (es) 2018-05-14
NO2017010I1 (no) 2017-03-27
AU2006239177B8 (en) 2012-02-16
PL2465580T3 (pl) 2014-05-30
EP1874117B8 (en) 2014-03-12
FIC20210017I1 (fi) 2021-06-10
US20170253616A1 (en) 2017-09-07
DK2465580T3 (en) 2014-03-10
EP1874117B1 (en) 2013-08-28
NO20075165L (no) 2007-11-22
HUS2100022I1 (hu) 2021-07-28
CY2021016I1 (el) 2021-10-15
EP3284519A8 (en) 2018-04-18
NO339525B1 (no) 2016-12-27
US20170224694A1 (en) 2017-08-10
US8778943B2 (en) 2014-07-15
US20150232479A1 (en) 2015-08-20
NO2017010I2 (no) 2017-03-27
KR101504998B1 (ko) 2015-03-23
MX2007013351A (es) 2008-01-21
EP3372281A1 (en) 2018-09-12
MA29460B1 (fr) 2008-05-02
IL186555A (en) 2016-10-31
EP3187225B1 (en) 2022-01-05
ES2906792T3 (es) 2022-04-20
HUE037795T2 (hu) 2018-09-28
EP3187225A1 (en) 2017-07-05
IL225207A (en) 2017-11-30
US8129385B2 (en) 2012-03-06
ES2743531T3 (es) 2020-02-19
HK1251191A1 (en) 2019-01-25
US9273065B2 (en) 2016-03-01
LU92446I2 (fr) 2015-10-29
EP2465580B1 (en) 2013-12-18
EP2527007B1 (en) 2016-03-30
PT3045206T (pt) 2018-07-05
US20240279238A1 (en) 2024-08-22
EP3045206B1 (en) 2018-03-28
US20170145033A1 (en) 2017-05-25
CA2606282C (en) 2016-04-26
US20160137666A1 (en) 2016-05-19
EP1874117A4 (en) 2009-12-30
US20200339598A1 (en) 2020-10-29
SI2465580T1 (sl) 2014-04-30
US10927129B2 (en) 2021-02-23
US20170369509A1 (en) 2017-12-28
NL301109I1 (nl) 2021-09-15
IL225206A (en) 2017-11-30
PL3284520T3 (pl) 2020-01-31
TWI378931B (en) 2012-12-11
NO2021018I1 (no) 2021-05-10
DK3284520T3 (da) 2019-09-16
CY1124601T1 (el) 2022-07-22
HUS2100023I1 (hu) 2021-07-28
KR20130133061A (ko) 2013-12-05
PT2465580E (pt) 2014-02-25
EP3284520B1 (en) 2019-06-05
US20140200209A1 (en) 2014-07-17
AU2006239177A1 (en) 2006-11-02
CY1116331T1 (el) 2017-02-08
BRPI0610030B8 (pt) 2022-01-11
NO2023042I1 (no) 2023-11-08
SI1874117T1 (sl) 2014-01-31
JP2008540343A (ja) 2008-11-20
MX312216B (en) 2013-08-12
EP3284519A1 (en) 2018-02-21
WO2006116764A1 (en) 2006-11-02
HUS1400039I1 (hu) 2016-08-29
ES2567197T3 (es) 2016-04-20
PL3372281T3 (pl) 2021-12-27
SI3045206T1 (en) 2018-07-31
NO20161315A1 (no) 2007-11-22
VN34404A1 (en) 2013-07-25
CY1120345T1 (el) 2019-07-10
CA2606282A1 (en) 2006-11-02
EA200702080A1 (ru) 2008-04-28
US20190152990A1 (en) 2019-05-23
KR101848819B1 (ko) 2018-04-16
KR101580310B1 (ko) 2016-01-04
HUE056603T2 (hu) 2022-02-28
TW200716635A (en) 2007-05-01
NL301109I2 (nl) 2021-09-15
NZ562339A (en) 2011-01-28
KR20160003889A (ko) 2016-01-11
US8410103B2 (en) 2013-04-02
SI3372281T1 (sl) 2021-11-30
US20160304535A1 (en) 2016-10-20
ES2437268T3 (es) 2014-01-09
CY1122052T1 (el) 2020-10-14
PL1874117T3 (pl) 2014-01-31
US20170224695A1 (en) 2017-08-10
ES2446324T3 (es) 2014-03-07
LUC00210I2 (enExample) 2022-10-07
US20130172559A1 (en) 2013-07-04
CY2014024I2 (el) 2025-05-09
EP3187226A1 (en) 2017-07-05
HK1249742A1 (en) 2018-11-09
EP3045206B2 (en) 2023-02-15
EP3372281B1 (en) 2021-07-07
LT3045206T (lt) 2018-06-11
EP2465580A1 (en) 2012-06-20
LTPA2014021I1 (lt) 2014-07-25
HUE044978T2 (hu) 2019-11-28
ES2667868T5 (es) 2023-06-01
JP2009079058A (ja) 2009-04-16
IL186555A0 (en) 2008-01-20
US20190284208A1 (en) 2019-09-19
LTPA2021512I1 (enExample) 2021-07-12
PT3372281T (pt) 2021-10-14
US20120115875A1 (en) 2012-05-10
IL215788A0 (en) 2011-12-29
US20170260203A1 (en) 2017-09-14
KR20140097438A (ko) 2014-08-06
US11267823B2 (en) 2022-03-08
US9051337B2 (en) 2015-06-09
ES2892304T3 (es) 2022-02-03
LTC1874117I2 (lt) 2025-03-25
PT1874117E (pt) 2013-10-17
LT3284520T (lt) 2019-09-25
PL3045206T3 (pl) 2018-08-31
HK1172282A1 (en) 2013-04-19
JP4295353B2 (ja) 2009-07-15
US20170267693A1 (en) 2017-09-21
MX302718B (es) 2012-08-27
BE2021C519I2 (enExample) 2025-12-10
FR14C0041I2 (fr) 2015-11-13
SI3187225T1 (sl) 2022-04-29
AU2006239177B2 (en) 2011-10-20
KR20080009733A (ko) 2008-01-29
LT3372281T (lt) 2021-12-10
NO340111B1 (no) 2017-03-13
US20160207939A1 (en) 2016-07-21
PT3284520T (pt) 2019-09-10
BRPI0610030A2 (pt) 2011-10-11
SI3284520T1 (sl) 2019-10-30
BRPI0610030B1 (pt) 2020-09-15
DK3372281T3 (da) 2021-09-27
EA014162B1 (ru) 2010-10-29
US20170209454A1 (en) 2017-07-27
EP1874117A1 (en) 2008-01-09
US20170029438A1 (en) 2017-02-02
DK1874117T3 (da) 2013-09-23
EP3045206A1 (en) 2016-07-20
CY2021016I2 (el) 2021-12-31
EP3284520A1 (en) 2018-02-21
EP2527007A1 (en) 2012-11-28
US20220213121A1 (en) 2022-07-07
DK3187225T3 (da) 2022-02-28
US20090318421A1 (en) 2009-12-24
CY2014024I1 (el) 2015-12-09
CY1115151T1 (el) 2015-12-09

Similar Documents

Publication Publication Date Title
KR101363875B1 (ko) Ｈｉｖ 통합효소 억제 활성을 가지는 다환식카르바모일피리돈 유도체
CN101212903A (zh) 具有hiv整合酶抑制活性的多环氨基甲酰基吡啶酮衍生物
HK1230121A1 (en) Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
HK1178473A (en) Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20071128

Patent event code: PA01051R01D

Comment text: International Patent Application

AMND Amendment
PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20110428

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130214

Patent event code: PE09021S01D

AMND Amendment
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20130425

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20130729

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130214

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
AMND Amendment
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20131025

PJ0201 Trial against decision of rejection

Patent event date: 20131025

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20130729

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20131128

Appeal identifier: 2013101007665

Request date: 20131025

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20131025

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20131025

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20130415

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20110428

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20071206

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20131128

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20131126

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20140211

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20140212

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
A101 Application to extend term of patent right by permit
PA0101 Application to register extension of term of patent right by permit, etc.

Patent event date: 20141128

Patent event code: PA01011R01D

Comment text: Application to Register Extension of Term of Patent Right by Permit, etc.

J202 Request for trial for correction [limitation]
PJ0202 Trial for correction

Comment text: Request for Trial

Patent event date: 20150129

Patent event code: PJ02022R01D

Comment text: Registration of Establishment

Patent event date: 20140211

Patent event code: PJ02021E01I

Appeal kind category: Correction

Decision date: 20151022

Request date: 20150129

Appeal identifier: 2015105000013

J301 Trial decision

Free format text: TRIAL DECISION FOR CORRECTION REQUESTED 20150129

Effective date: 20151022

Free format text: TRIAL NUMBER: 2015105000013; TRIAL DECISION FOR CORRECTION REQUESTED 20150129

Effective date: 20151022

PJ1301 Trial decision

Patent event code: PJ13011S03D

Patent event date: 20151022

Comment text: Trial Decision on Correction (Patent, Utility Model)

Appeal kind category: Correction

Request date: 20150129

Decision date: 20151022

Appeal identifier: 2015105000013

PG1701 Publication of correction

Publication date: 20151117

FPAY Annual fee payment

Payment date: 20161229

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20161229

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20171228

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20181227

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20181227

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20191227

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20201224

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20220125

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20240130

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20250210

Start annual number: 12

End annual number: 12